MiniMed Group
MiniMed Group, Inc.
Key figures
Period 2025-04-26 to 2026-04-24ConsolidatedU.S. GAAP
RevenueDisclosed
US$3.1B
Operating marginCalculated
-6.1%
Net assets to total assetsCalculated
78.0%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-6.1%
Growth (revenue, 2-year average)
★★★★☆position among all companies
12.1%
Capital efficiency
★☆☆☆☆position among all companies
-9.2%
Revenue and profit
Performance, financial position and capital allocation
MiniMed Group
Recent performance trends
MiniMed Group
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | Could not be retrieved | Could not be retrieved | US$2.5 billion | US$2.7 billion | US$3.1 billion |
| Operating income | Could not be retrieved | Could not be retrieved | US$-69.00 million | US$-0.1 billion | US$-0.2 billion |
| Net income | Could not be retrieved | Could not be retrieved | US$-0.1 billion | US$-0.2 billion | US$-0.3 billion |
| Total assets | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$4.2 billion | US$4.6 billion |
| Shareholders' equity | Could not be retrieved | Could not be retrieved | US$3.4 billion | US$3.3 billion | US$3.6 billion |
| Net cash provided by (used in) operating activities | Could not be retrieved | Could not be retrieved | US$41.00 million | US$0.1 billion | US$-0.2 billion |
| Net cash provided by (used in) investing activities | Could not be retrieved | Could not be retrieved | US$-0.2 billion | US$-0.2 billion | US$-0.2 billion |
| Net cash provided by (used in) financing activities | Could not be retrieved | Could not be retrieved | US$0.1 billion | US$10.00 million | US$0.7 billion |
| Cash and cash equivalents | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$11.00 million | US$0.3 billion |
Revenue scale in the same industry
MiniMed Group
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 37 companies
- 41 TeradyneFY Dec 2025 US$3.2B
- 42 WatersFY Dec 2025 US$3.2B
- 43 MiniMed GroupThis companyFY Apr 2026 US$3.1B
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.2 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$-0.2 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.2 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$3.6 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0 | Consolidated | Disclosed |
| Net assets | US$3.6 billion | Consolidated | Disclosed |
| Net sales | US$3.1 billion | Consolidated | Disclosed |
| Operating income | US$-0.2 billion | Consolidated | Disclosed |
| Net income | US$-0.3 billion | Consolidated | Disclosed |
| Total assets | US$4.6 billion | Consolidated | Disclosed |
| Operating margin | -6.1% | Consolidated | Calculated |
| Net assets to total assets | 78.0% | Consolidated | Calculated |
| Net margin | -10.7% | Consolidated | Calculated |
| Return on equity | -9.2% | Consolidated | Calculated |